Phase 2, double-blind, randomized, placebo-controlled, 4-arm study to study symptoms, function, health-related quality of life, and safety of repeated subcutaneous administration of Ponsegromab compared to placebo in adult participants with heart failure
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: PFIZER, SLU
- Phase: II
- Execution start: 02/12/2022
- End of execution: 30/10/2024
- IP: SILVIA LOPEZ FERNANDEZ